X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (476) 476
Publication (32) 32
Book Review (12) 12
Book Chapter (4) 4
Magazine Article (4) 4
Conference Proceeding (1) 1
Dissertation (1) 1
Web Resource (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (330) 330
index medicus (248) 248
quinazolines - therapeutic use (203) 203
female (145) 145
lung neoplasms - drug therapy (124) 124
carcinoma, non-small-cell lung - drug therapy (121) 121
oncology (120) 120
male (119) 119
quinazolines - economics (106) 106
antineoplastic agents - therapeutic use (102) 102
quinazolines - pharmacology (102) 102
erlotinib hydrochloride (97) 97
middle aged (91) 91
chemotherapy (87) 87
quinazolines - administration & dosage (87) 87
aged (82) 82
erlotinib (77) 77
cancer (72) 72
gefitinib (70) 70
chemistry, organic (66) 66
cost-benefit analysis (65) 65
treatment outcome (65) 65
animals (63) 63
adult (60) 60
pharmacology & pharmacy (58) 58
protein kinase inhibitors - therapeutic use (57) 57
quinazolines - adverse effects (57) 57
antineoplastic combined chemotherapy protocols - therapeutic use (55) 55
care and treatment (55) 55
antineoplastic agents - economics (54) 54
quinazolines - chemistry (51) 51
lung cancer (47) 47
analysis (45) 45
lung neoplasms - pathology (44) 44
derivatives (43) 43
carcinoma, non-small-cell lung - pathology (42) 42
mutation (42) 42
carcinoma, non-small-cell lung - economics (41) 41
lung cancer, non-small cell (41) 41
lung neoplasms - economics (41) 41
quinazolines (41) 41
receptor, epidermal growth factor - antagonists & inhibitors (41) 41
aged, 80 and over (40) 40
disease-free survival (40) 40
quinazoline (40) 40
research (40) 40
therapy (40) 40
chemistry, medicinal (36) 36
protein kinase inhibitors - economics (36) 36
inhibitors (35) 35
breast neoplasms - drug therapy (34) 34
drug costs (33) 33
growth-factor receptor (33) 33
receptor, epidermal growth factor - genetics (33) 33
quinazolines - chemical synthesis (32) 32
randomized controlled trials as topic (32) 32
respiratory system (31) 31
trial (31) 31
antineoplastic agents - pharmacology (30) 30
docetaxel (30) 30
drug therapy (30) 30
survival analysis (30) 30
breast cancer (29) 29
chemistry, multidisciplinary (29) 29
survival (29) 29
lung neoplasms - mortality (28) 28
non-small cell lung cancer (28) 28
antineoplastic combined chemotherapy protocols - economics (27) 27
carcinoma, non-small-cell lung - mortality (27) 27
deoxycytidine - analogs & derivatives (26) 26
hematology, oncology and palliative medicine (26) 26
medicine & public health (26) 26
quality-adjusted life years (26) 26
lung neoplasms - genetics (25) 25
antineoplastic agents (24) 24
antineoplastic agents - adverse effects (24) 24
medicine, general & internal (24) 24
quinazoline derivatives (24) 24
time factors (24) 24
colorectal neoplasms - drug therapy (23) 23
epidermal growth factor (23) 23
molecular structure (23) 23
trastuzumab (23) 23
united states (23) 23
adenocarcinoma - drug therapy (22) 22
carcinoma, non-small-cell lung - genetics (22) 22
cell lung-cancer (22) 22
metastasis (22) 22
neoplasm staging (22) 22
adenocarcinoma (21) 21
cancer therapies (21) 21
cost-effectiveness (21) 21
egfr (21) 21
open-label (21) 21
phase-iii trial (21) 21
synthesis (21) 21
antimitotic agents (20) 20
antineoplastic agents - administration & dosage (20) 20
biochemistry & molecular biology (20) 20
clinical trials as topic (20) 20
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Value in Health, ISSN 1098-3015, 2015, Volume 18, Issue 6, pp. 774 - 782
Abstract Objectives To determine the cost-effectiveness of tyrosine kinase inhibitors erlotinib or afatinib, or chemotherapy cisplatin-pemetrexed, for... 
Internal Medicine | EGFR mutation-positive NSCLC | cost-effectiveness | treatment | value-of-information | expected value of perfect information | METAANALYSIS | ADENOCARCINOMA | ASIAN PATIENTS | OPEN-LABEL | CHEMOTHERAPY | ECONOMIC BURDEN | RANDOMIZED PHASE-3 TRIAL | DECISION-MAKING | HEALTH CARE SCIENCES & SERVICES | HEALTH POLICY & SERVICES | EFFECTIVENESS ACCEPTABILITY CURVES | ECONOMICS | INHIBITORS | Lung Neoplasms - drug therapy | Receptor, Epidermal Growth Factor - genetics | Lung Neoplasms - mortality | Humans | Models, Economic | Protein Kinase Inhibitors - adverse effects | Erlotinib Hydrochloride - economics | Clinical Trials, Phase III as Topic | Comparative Effectiveness Research | Pemetrexed - economics | Time Factors | Quinazolines - administration & dosage | Quality-Adjusted Life Years | Erlotinib Hydrochloride - adverse effects | Lung Neoplasms - enzymology | Protein Kinase Inhibitors - economics | Cisplatin - economics | Molecular Targeted Therapy - economics | Disease Progression | Protein Kinase Inhibitors - administration & dosage | Pemetrexed - administration & dosage | Quality of Life | Carcinoma, Non-Small-Cell Lung - enzymology | Mutation | Quinazolines - economics | Drug Costs | Markov Chains | Uncertainty | United States | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Cisplatin - administration & dosage | Patient Selection | Antineoplastic Combined Chemotherapy Protocols - economics | Lung Neoplasms - genetics | Carcinoma, Non-Small-Cell Lung - genetics | Decision Support Techniques | Erlotinib Hydrochloride - administration & dosage | Treatment Outcome | Carcinoma, Non-Small-Cell Lung - mortality | Randomized Controlled Trials as Topic | Carcinoma, Non-Small-Cell Lung - economics | Disease-Free Survival | Pemetrexed - adverse effects | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Cost-Benefit Analysis | Quinazolines - adverse effects | Cisplatin - adverse effects | Receptor, Epidermal Growth Factor - antagonists & inhibitors | Lung Neoplasms - economics | Carcinoma, Non-Small-Cell Lung - drug therapy
Journal Article
PLoS ONE, ISSN 1932-6203, 03/2013, Volume 8, Issue 3, p. e55917
Introduction: Lung cancer, the most prevalent malignant cancer in the world, remains a serious threat to public health. Recently, a large number of studies... 
PHASE-III TRIAL | GENE-MUTATIONS | GROWTH-FACTOR RECEPTOR | MULTIDISCIPLINARY SCIENCES | CLINICAL-TRIALS | 2ND-LINE TREATMENT | ECONOMIC OUTCOMES | OPEN-LABEL | GEFITINIB THERAPY | COMBINATION | EGFR | Erlotinib Hydrochloride | Lung Neoplasms - drug therapy | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Costs and Cost Analysis | Deoxycytidine - administration & dosage | Humans | Carboplatin - administration & dosage | Male | Models, Economic | Deoxycytidine - economics | Carboplatin - economics | Carcinoma, Non-Small-Cell Lung - economics | Time Factors | Antineoplastic Combined Chemotherapy Protocols - economics | Female | Quinazolines - administration & dosage | Lung Neoplasms - economics | Carcinoma, Non-Small-Cell Lung - drug therapy | Quinazolines - economics | Far East | Deoxycytidine - analogs & derivatives | Tyrosine | Economic aspects | Cost benefit analysis | Lung cancer, Non-small cell | Chemotherapy | Erlotinib | Gene mutations | Analysis | Markov processes | Genetic aspects | Health aspects | Medical care, Cost of | Cancer | Health care | Parameter estimation | Gemcitabine | Lung cancer | Clinical trials | Markov chains | Parameter sensitivity | Cancer therapies | Epidermal growth factor | Platinum | Parameter uncertainty | Protein-tyrosine kinase | Pharmaceutical sciences | Public health | Sensitivity analysis | Statistical analysis | Life expectancy | Small cell lung carcinoma | Epidermal growth factor receptors | Health risks | Non-small cell lung carcinoma | Patients | Hospitals | Pharmacy | Point mutation | Carboplatin | Mutation | Cost analysis
Journal Article
Journal Article
Cancer, ISSN 0008-543X, 02/2012, Volume 118, Issue 4, pp. 1032 - 1039
Journal Article
Lung Cancer, ISSN 0169-5002, 2015, Volume 90, Issue 1, pp. 71 - 77
Highlights • Cost-effectiveness of first-line gefitinib therapy with EGFR testing is examined using Markov model. • Combination use of gefitinib and EGFR... 
Hematology, Oncology and Palliative Medicine | Pulmonary/Respiratory | Pharmacoeconomics | Cost-effectiveness analysis | Individualized medicine | Gefitinib | Non-small cell lung cancer | ONCOLOGY | RESPIRATORY SYSTEM | ADENOCARCINOMA | PHASE-III | OPEN-LABEL | CHEMOTHERAPY | GEMCITABINE | DNA Mutational Analysis - economics | Lung Neoplasms - drug therapy | Receptor, Epidermal Growth Factor - genetics | Markov Chains | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Humans | Lung Neoplasms - pathology | DNA Mutational Analysis - methods | Young Adult | Antineoplastic Combined Chemotherapy Protocols - economics | Adult | Quinazolines - administration & dosage | Paclitaxel - administration & dosage | Precision Medicine | Carcinoma, Non-Small-Cell Lung - pathology | Lung Neoplasms - genetics | Economics, Pharmaceutical | Paclitaxel - economics | Protein Kinase Inhibitors - economics | Carcinoma, Non-Small-Cell Lung - genetics | Japan | Decision Support Techniques | Carboplatin - administration & dosage | Carboplatin - economics | Carcinoma, Non-Small-Cell Lung - economics | Protein Kinase Inhibitors - administration & dosage | Administration, Intravenous | Cost-Benefit Analysis | Adolescent | Receptor, Epidermal Growth Factor - antagonists & inhibitors | Lung Neoplasms - economics | Carcinoma, Non-Small-Cell Lung - drug therapy | Mutation | Quinazolines - economics | Analysis | Pharmacy | Markov processes | Drugstores | Cost benefit analysis | Lung cancer, Non-small cell
Journal Article
The European Journal of Health Economics, ISSN 1618-7598, 10/2012, Volume 13, Issue 5, pp. 589 - 603
Background In a phase III trial of women with HER2+ metastatic breast cancer (MBC) previously treated with trastuzumab, an anthracycline, and taxanes... 
Health care costs | Chemotherapy | Sensitivity analysis | Cost estimation models | Cost estimates | Utilities costs | Experimentation | Medications | Breast cancer | Cost efficiency | Economics | Cost and cost analysis | Economic Policy | Medicine & Public Health | Statistics for Life Sciences, Medicine, Health Sciences | Statistics for Business/Economics/Mathematical Finance/Insurance | I1 | Public Finance & Economics | Health Informatics | Breast neoplasms, secondary | Public Health/Gesundheitswesen | Lapatinib | Secondary | Breast neoplasms | SURVIVAL | UNITED-KINGDOM | CARE | TRIAL | GROWTH-FACTOR RECEPTOR | UNCERTAINTY | HEALTH POLICY & SERVICES | EXPERIENCE | PROGRESSION | Confidence Intervals | State Medicine | Women's Health | Breast Neoplasms - economics | Capecitabine | Humans | Fluorouracil - economics | Antineoplastic Agents - therapeutic use | Models, Economic | Antibodies, Monoclonal, Humanized - economics | Fluorouracil - therapeutic use | Deoxycytidine - therapeutic use | Female | Drug Therapy, Combination | Quality-Adjusted Life Years | Antibodies, Monoclonal, Humanized - therapeutic use | Fluorouracil - analogs & derivatives | Probability | Antimetabolites, Antineoplastic - economics | United Kingdom | Deoxycytidine - economics | Breast Neoplasms - drug therapy | Antineoplastic Agents - economics | Antimetabolites, Antineoplastic - therapeutic use | Breast Neoplasms - psychology | Quinazolines - therapeutic use | Cost-Benefit Analysis | Quinazolines - economics | Deoxycytidine - analogs & derivatives | Trastuzumab | Studies | Economic models | Health care expenditures | Epidermal growth factor | Economic theory | Metastasis | Cost analysis | Economic statistics
Journal Article
BMC Pulmonary Medicine, ISSN 1471-2466, 12/2014, Volume 14, Issue 1, pp. 192 - 192
Journal Article
Value in Health, ISSN 1098-3015, 2009, Volume 12, Issue 1, pp. 20 - 27
Journal Article
PharmacoEconomics, ISSN 1170-7690, 2009, Volume 27, Issue 2, pp. 113 - 125
The purpose of this article is to review the economics of treatments for non-small cell lung cancer (NSCLC). We systematically analysed the cost effectiveness... 
Quality of Life Research | Health Economics | Health Administration | Pharmacoeconomics and Health Outcomes | Medicine & Public Health | COST-MINIMIZATION ANALYSIS | SUPPORTIVE CARE | COMPARING GEMCITABINE/CISPLATIN | VINORELBINE PLUS CISPLATIN | CHEMOTHERAPY REGIMENS | CLINICAL-TRIALS | RANDOMIZED-TRIAL | PHARMACOLOGY & PHARMACY | GUIDELINES 2ND EDITION | QUALITY-OF-LIFE | HOSPITAL COSTS | Erlotinib Hydrochloride | Carcinoma, Non-Small-Cell Lung - radiotherapy | Glutamates - therapeutic use | Lung Neoplasms - drug therapy | Carcinoma, Non-Small-Cell Lung - surgery | Guanine - analogs & derivatives | Humans | Guanine - economics | Lung Neoplasms - radiotherapy | Pemetrexed | Combined Modality Therapy - economics | Glutamates - economics | Carcinoma, Non-Small-Cell Lung - economics | Taxoids - therapeutic use | Taxoids - economics | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Quinazolines - therapeutic use | Cost-Benefit Analysis | Antineoplastic Combined Chemotherapy Protocols - economics | Lung Neoplasms - surgery | Lung Neoplasms - economics | Carcinoma, Non-Small-Cell Lung - drug therapy | Quinazolines - economics | Guanine - therapeutic use | Chemotherapy | Care and treatment | Economic aspects | Diagnosis | Radiotherapy | Lung cancer, Non-small cell | Health aspects | Cancer | Studies | Health care expenditures | Health economics | Lung cancer | Medical treatment | Life Sciences | Taxoids | Carcinoma, Non-Small-Cell Lung | Antineoplastic Combined Chemotherapy Protocols | Santé publique et épidémiologie | Combined Modality Therapy | Quinazolines | Glutamates | Lung Neoplasms | Guanine
Journal Article
BMC Cancer, ISSN 1471-2407, 12/2014, Volume 14, Issue 1, p. 953
Journal Article
Oncotarget, ISSN 1949-2553, 2017, Volume 8, Issue 6, pp. 9996 - 10006
Tyrosine kinase inhibitors of the epidermal growth factor receptor (EGFR) are becoming the standard treatment option for patients with advanced non-small cell... 
EGFR mutation | Icotinib | Gefitinib | Cost-effectiveness | Non-small cell lung cancer | non-small cell lung cancer | cost-effectiveness | MULTICENTER | ADENOCARCINOMA | gefitinib | OPEN-LABEL | PHASE-3 | NETWORK METAANALYSIS | MAINTENANCE THERAPY | CELL BIOLOGY | PLATINUM-BASED CHEMOTHERAPY | DOUBLE-BLIND | ERLOTINIB | icotinib | PLUS | Drug Costs | Lung Neoplasms - drug therapy | Receptor, Epidermal Growth Factor - genetics | Humans | Precision Medicine - economics | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Lung Neoplasms - pathology | Models, Economic | Protein Kinase Inhibitors - adverse effects | Crown Ethers - therapeutic use | Pemetrexed - economics | Time Factors | China | Computer Simulation | Antineoplastic Combined Chemotherapy Protocols - economics | Crown Ethers - adverse effects | Carcinoma, Non-Small-Cell Lung - pathology | Lung Neoplasms - genetics | Quality-Adjusted Life Years | Lung Neoplasms - enzymology | Protein Kinase Inhibitors - economics | Carcinoma, Non-Small-Cell Lung - genetics | Treatment Outcome | Crown Ethers - economics | Molecular Targeted Therapy - economics | Disease-Free Survival | Pemetrexed - adverse effects | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Pemetrexed - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Quinazolines - therapeutic use | Cost-Benefit Analysis | Quinazolines - adverse effects | Receptor, Epidermal Growth Factor - antagonists & inhibitors | Carcinoma, Non-Small-Cell Lung - drug therapy | Carcinoma, Non-Small-Cell Lung - enzymology | Mutation | Quinazolines - economics
Journal Article